Treatment of subretinal neovascular membrane in a patient with membranoproliferative glomerulonephritis type II.
A 29-year-old woman with membranoproliferative glomerulonephritis type II presented with decreased vision due to choroidal neovascular membrane. She was treated with monthly intravitreal injections of bevacizumab. Although there was dramatic improvement in her vision after the third injection, it continued to improve through the ninth monthly injection. Despite recent reports of renal side effects of systemic bevacizumab, patients with preexisting renal disease treated by the authors did not demonstrate any loss of renal function 1 year after treatment.
Farah
Samer E
SE
Albert Einstein College of Medicine, Pelham Bay, NY 10461, USA.
Fazelat
Ahad
A
Frei
Gill
G
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D015432:Glomerulonephritis, Membranoproliferative / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007267:Injections; D007677:Kidney Function Tests; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D000069579:Ranibizumab; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab